Loading...
Syngene International Limited
SYNGENE.NS•NSE
Healthcare
Biotechnology
₹-5.30(-1.34%)
Indian Market opens in 34h 48mSyngene International Limited (SYNGENE.NS) AI-Powered Stock Analysis
See how Syngene International Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerSyngene International Limited (SYNGENE.NS) Stock Overall Grade
Syngene International Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Syngene International Limited's overall stock rating.
Forecast
A+Score
100/100Financial Growth
A+Score
90/100Fundamental Growth
AScore
83/100Key Ratios
BScore
62/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Syngene International Limited (SYNGENE.NS) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (90/100, A+) and Fundamental Growth (83/100, A) highlight its stability, while Key Ratios (62/100, B) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Syngene International Limited stock grade, including financials, comparisons, and forecasts.